Moving Beyond Staging Alone in Melanoma: GEP Testing Refines Mortality Risk

Castle Biosciences’ DecisionDx-Melanoma test refines mortality risk within American Joint Committee on Cancer (AJCC) Cancer Staging System for patients with cutaneous melanoma, according to research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.